Download The Anti-SaaS Guide for Investing in Industrial Biotech
Building the next winners in industrial biotech. Drop Your Info Below For Instant Access.
The anti-saas Guide to biotech
Stop Investing in Industrial Biotech Like It’s SaaS
Industrial biotech is built with atoms, scaled through physical infrastructure, and financed on timelines that software investors routinely misread.
Industrial biotech does not fail because the science is uninteresting. It fails when investors apply software assumptions to businesses that must build plants, secure feedstock, validate production at larger scales, and finance years of engineering work before reaching full commercial output.
The Anti-SaaS Guide to Investing in Industrial Biotech explains how to evaluate these companies on their own terms. Instead of chasing the largest possible market, it focuses on reachable profit pools, proven science, cost parity, commercial demand, and the engineering milestones that create value.
It also lays out a portfolio strategy designed for capital-intensive, milestone-gated companies- where returns depend not only on choosing the right molecules, but on preserving ownership, reserving capital intelligently, and using grants, debt, project finance, offtake agreements, and strategic partners to fund scale.
Inside the playbook, you’ll learn why successful investing in industrial biotech requires a different approach:
Profit pools matter more than headline TAM
Working science is the starting line, not the finish line
Engineering and scale-up milestones should drive investment decisions
Cost parity and real customer demand must be established early
Portfolio reserves should follow milestones, not software-style growth curves
The strongest industrial biotech portfolios are not built by importing a software venture playbook. They are constructed around step-function growth, disciplined selection, diversified scale-up risk, and a capital stack designed for physical assets.
Download the guide to learn how First Bight Ventures evaluates industrial biotech companies, finances engineering risk, and builds portfolios capable of surviving the long climb from lab validation to commercial scale.
Our analysis breaks down key insights to scale bio.
Driving sustainable innovation
The Leading Investor in Biomanufacturing
First Bight Ventures is an early stage biomanufacturing investor.
In our first fund, we invested in 7 startups.
Now, we are helping other investors and corporations scale the use of biology throughout manufacturing.
Check Out Our Awesome Portfolio Companies
Beyond Capital
We Partner With Startups To Scale Impact
If you are looking for silent capital, you are in the wrong place.
We Lead Rounds
We write first checks for
seed through series A.
We Take Board Seats
We are actively involved in
strategy and governance.
We Make Introductions
We leverage our relationships to drive meaningful partnerships.
We Drive Efficiencies
We help our portfolio companies proficiently scale operations.
We Mitigate Risks
We identify and reduce scale up risks to increase shareholder value.
We Love Science
We nerd out on technology
and how it drives impact.
TESTIMONIALS
Why Work With Us?
We have created the leading biomanufacturing venture ecosystem.
“First Bight knows how to derisk industrial biotech investments.”
“In a complex, long gestation and capital-intensive space, First Bight stands out for how it actively drives progress; not just funds it.”
- Mario Maia, Ventures @ Novozymes
“Connecting all the dots for startups and corporates."
“Veronica & the First Bight team understand how we fit into the ecosystem, & make valuable introductions to key industry partners.”
- Noah Helman, CEO @ iMicrobes
"First Bight turns lab scale into industrial powerhouses."
“Veronica & the team dive in early, bring Tesla-level technical rigor, and help founders de-risk scale-up so their companies can print cash.”
- Dave McClure, Founder @ 500 Startups
Smiles expected, not guaranteed.
Copyrights 2025 | First Bight Ventures™ | Terms & Conditions
520 Post Oak Blvd Suite #825 Houston, TX 77027